BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances
BioCryst Pharmaceuticals Inc · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $8.57
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS